ArticleInternational endodontic journal2026
Optimal Hypoxia Mimetic Small Molecules for Enhancing Angiogenic Properties of Stem Cells From Human Exfoliated Deciduous Teeth.
Article in International endodontic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimHypoxic preconditioning of cells holds promise for regenerative therapies, yet identifying effective and safe methods for clinical application remains challenging. We aimed to determine optimal hypoxia-mimetic small molecules (SMs) that stabilize hypoxia-inducible factor-1α (HIF-1α) and their dosages for hypoxic preconditioning in stem cells from human exfoliated deciduous teeth (SHED), and to examine their effects on SHED angiogenic properties. METHODOLOGY: A systematic approach integrating transcriptomics, bioinformatics, and experimental validation was employed. RNA sequencing data from prolyl-hydroxylase domain 2-knockdown SHED were queried against the Connectivity Map to identify the top 3 SMs that most closely mimic this hypoxic signature. To establish causality and mechanism, the selective Bcl-2 inhibitor venetoclax and HIF-1α siRNA were used. Candidate compounds and conventional agents (CoCl
resultsCoCl
conclusionsTW-37 (10 μM), ML228 (1 μM), and CPX (7 μM) are promising hypoxia-mimetic regimens in this proof-of-concept model. TW-37 acts through a specific, reversible HIF-1α-dependent mechanism, demonstrating a favorable balance between angiogenic enhancement and preliminary safety in regenerative endodontics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.